Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Muhammad Tufail & Changxin Wu. (2023) RANK pathway in cancer: underlying resistance and therapeutic approaches. Journal of Chemotherapy 35:5, pages 369-382.
Read now
Read now
M Baud’huin, L Duplomb, C Ruiz Velasco, Y Fortun, D Heymann & M Padrines. (2007) Key roles of the OPG–RANK–RANKL system in bone oncology. Expert Review of Anticancer Therapy 7:2, pages 221-232.
Read now
Read now
Klaus Podar, Teru Hideshima, Dharminder Chauhan & Kenneth C Anderson. (2005) Targeting signalling pathways for the treatment of multiple myeloma. Expert Opinion on Therapeutic Targets 9:2, pages 359-381.
Read now
Read now
Articles from other publishers (39)
Marta Diaz‐delCastillo, Michael Tveden Gundesen, Christian Walther Andersen, Anne Lerberg Nielsen, Hanne Elisabeth Højsgaard Møller, Pernille Just Vinholt, Jon Thor Asmussen, Ida Bruun Kristensen, Charlotte Guldborg Nyvold, Niels Abildgaard, Thomas Levin Andersen & Thomas Lund. (2023) Increased Bone Volume by Ixazomib in Multiple Myeloma: 3‐Month Results from an Open Label Phase 2 Study. Journal of Bone and Mineral Research 38:5, pages 639-649.
Crossref
Crossref
Aiken Dao, Michelle M McDonald, Paul B. Savage, David G. Little & Aaron Schindeler. (2022) Preventing osteolytic lesions and osteomyelitis in multiple myeloma. Journal of Bone Oncology, pages 100460.
Crossref
Crossref
Maroun Bou Zerdan, Lewis Nasr, Joseph Kassab, Ludovic Saba, Myriam Ghossein, Marita Yaghi, Barbara Dominguez & Chakra P Chaulagain. (2022) Adhesion molecules in multiple myeloma oncogenesis and targeted therapy. International Journal of Hematologic Oncology 11:2.
Crossref
Crossref
Thomas A. Burley, Emma Kennedy, Georgia Broad, Melanie Boyd, David Li, Timothy Woo, Christopher West, Eleni E. Ladikou, Iona Ashworth, Christopher Fegan, Rosalynd Johnston, Simon Mitchell, Simon P. Mackay, Andrea G. S. Pepper & Chris Pepper. (2022) Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma. Cancers 14:6, pages 1489.
Crossref
Crossref
Fawzy Ali Saad. (2021) Proteomics: an emerging tool for the discovery of bone mineral density molecular pathways. Journal of Proteins and Proteomics 12:4, pages 247-256.
Crossref
Crossref
Christian Ramos-Peñafiel, Cristina Madera-Maldonado, Adrián Santoyo Sánchez, Erika Rojas-González, Irma Olarte-Carrillo, Adolfo Martínez-Tovar & Juan Collazo-Jaloma. (2021) Mieloma múltiple: consideraciones especiales al diagnóstico. Revista Colombiana de Cancerología 25:2.
Crossref
Crossref
Rebecca E. Andrews, Andrew D. Chantry & A. John Ashcroft. 2021. Management of Bone Disease and Kidney Failure in Multiple Myeloma. Management of Bone Disease and Kidney Failure in Multiple Myeloma
7
36
.
Rahul Kumar, P. Sonika Godavarthy & Daniela S. Krause. (2018) The bone marrow microenvironment in health and disease at a glance. Journal of Cell Science 131:4.
Crossref
Crossref
Sophie Roux. (2017) L’os du myélome multiple : physiopathologie. Revue du Rhumatisme Monographies 84:2, pages 181-186.
Crossref
Crossref
Jiri Minarik, Zuzana Hermanova, Pavla Petrova, Jan Hrbek, Jana Zapletalova, Petra Krhovska, Patrik Flodr, Tomas Pika, Jaroslav Bacovsky, Pavla Flodrova, Miroslav Herman & Vlastimil Scudla. (2016) Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers. European Journal of Haematology 97:2, pages 201-207.
Crossref
Crossref
Eva González-Suárez & Adrián Sanz-Moreno. (2016) RANK as a therapeutic target in cancer. The FEBS Journal 283:11, pages 2018-2033.
Crossref
Crossref
S. Roux. (2015) Manifestaciones osteoarticulares de las hemopatías malignas (excluido el mieloma). EMC - Aparato Locomotor 48:2, pages 1-10.
Crossref
Crossref
XIAOMING LI, YAOMING LIU, BIN WU, ZHILONG DONG, YICHEN WANG, JIANZHONG LU, PING SHI, WENLONG BAI & ZHIPING WANG. (2014) Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Oncology Reports 32:6, pages 2605-2611.
Crossref
Crossref
R. E. Walker, M. A. Lawson, C. H. Buckle, J. A. Snowden & A. D. Chantry. (2014) Myeloma bone disease: pathogenesis, current treatments and future targets. British Medical Bulletin 111:1, pages 117-138.
Crossref
Crossref
Jorge M. Pacheco, Francisco C. Santos & David Dingli. (2014) The ecology of cancer from an evolutionary game theory perspective. Interface Focus 4:4, pages 20140019.
Crossref
Crossref
Hisataka Yasuda. (2013) RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World Journal of Orthopedics 4:4, pages 207.
Crossref
Crossref
Y Sambandam, K Sundaram, A Liu, K L Kirkwood, W L Ries & S V Reddy. (2012) CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor–bone microenvironment. Oncogene 32:1, pages 97-105.
Crossref
Crossref
E. Spas-Defasque, A. Renaud, B. Cortet, P. Herbinet, N. Boutry & A. Cotten. 2013. Imagerie Musculosquelettique : Pathologies G?n?rales. Imagerie Musculosquelettique : Pathologies G?n?rales
383
444
.
Joan Bladé & Laura Rosiñol. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
665
680
.
Heba M. Saad Eldien, Hossam El-Din M. Omar, Mohammed S. Badary & Bushra Y. Al-Khatib. (2012) The possible protective and therapeutic roles of fucoidan in cyclosporine-induced histological changes in the bone marrow and spleen in rats. The Egyptian Journal of Histology 35:3, pages 383-397.
Crossref
Crossref
Stephen McManus, Estelle Chamoux, Martine Bisson & Sophie Roux. (2011) Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro. Apoptosis 17:2, pages 121-131.
Crossref
Crossref
Caterina Musolino & Alessandro Allegra. 2012. Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach
35
48
.
Tetsuro Enomoto, Yuriko Furuya, Yoshiya Tomimori, Kaoru Mori, Jun-ichi Miyazaki & Hisataka Yasuda. (2010) Establishment of a new murine model of hypercalcemia with anorexia by overexpression of soluble receptor activator of NF-κB ligand using an adenovirus vector. Journal of Bone and Mineral Metabolism 29:4, pages 414-421.
Crossref
Crossref
Mireya Fernández, Ana M Pino, Paula Figueroa & Juan P Rodríguez. (2010) The increased expression of receptor activator of nuclear‐κB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate. Journal of Cellular Biochemistry 111:1, pages 130-137.
Crossref
Crossref
D Dingli, F A C C Chalub, F C Santos, S Van Segbroeck & J M Pacheco. (2009) Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. British Journal of Cancer 101:7, pages 1130-1136.
Crossref
Crossref
E. Terpos, O. Sezer, P.I. Croucher, R. García-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Bladé, M. Cavo, M. Delforge, M.-A. Dimopoulos, T. Facon, M. Macro, A. Waage & P. Sonneveld. (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Annals of Oncology 20:8, pages 1303-1317.
Crossref
Crossref
Allen P. Anandarajah. (2009) Role of RANKL in bone diseases. Trends in Endocrinology & Metabolism 20:2, pages 88-94.
Crossref
Crossref
Allan Lipton & Susie Jun. (2008) RANKL inhibition in the treatment of bone metastases. Current Opinion in Supportive & Palliative Care 2:3, pages 197-203.
Crossref
Crossref
Roger H. Weenig. (2008) Pathogenesis of calciphylaxis: Hans Selye to nuclear factor κ-B. Journal of the American Academy of Dermatology 58:3, pages 458-471.
Crossref
Crossref
G. David Roodman & William C. Dougall. (2008) RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treatment Reviews 34:1, pages 92-101.
Crossref
Crossref
Roger H. Weenig & Khosrow Mehrany. (2008) Dermal and Pannicular Manifestations of Internal Malignancy. Dermatologic Clinics 26:1, pages 31-43.
Crossref
Crossref
Min Li, Jerome L. Maderdrut, Juan J.L. Lertora & Vecihi Batuman. (2007) Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: A case study. Peptides 28:9, pages 1891-1895.
Crossref
Crossref
Min Li, Shirley Cortez, Tomoya Nakamachi, Vecihi Batuman & Akira Arimura. (2006) Pituitary Adenylate Cyclase-Activating Polypeptide Is a Potent Inhibitor of the Growth of Light Chain-Secreting Human Multiple Myeloma Cells. Cancer Research 66:17, pages 8796-8803.
Crossref
Crossref
Peter Oelzner, Gabriele Lehmann, Thorsten Eidner, Sybille Franke, Andreas Müller, Gunter Wolf & Gert Hein. (2006) Hypercalcemia in rheumatoid arthritis: relationship with disease activity and bone metabolism. Rheumatology International 26:10, pages 908-915.
Crossref
Crossref
Sophie Roux. (2006) Les inhibiteurs de?RANKL?: quel?avenir??. Revue du Rhumatisme 73:3, pages 212-214.
Crossref
Crossref
Sophie Roux. (2006) RANKL inhibitors: a?bright future?. Joint Bone Spine 73:2, pages 129-131.
Crossref
Crossref
S. Roux & X. Mariette. (2006) Manifestations ostéoarticulaires des hémopathies malignes (myélome exclu). EMC - Appareil locomoteur 1:1, pages 1-11.
Crossref
Crossref
S. Roux & X. Mariette. (2005) Manifestations ostéoarticulaires des hémopathies malignes (myélome exclu). EMC - Rhumatologie-Orthopédie 2:2, pages 109-124.
Crossref
Crossref
S. Roux & X. Mariette. (2005) Manifestaciones osteoarticulares de las hemopatías malignas (excepto el mieloma). EMC - Aparato Locomotor 38:2, pages 1-12.
Crossref
Crossref